The FDA will now review the product in adults 50 to 64 through a regular pathway, and adults over 65 via accelerated approval with a requirement to run a post-marketing study. The agency will aim to review the vaccine by Aug. 5.
www.statnews.com/2026/02/18/fda-moderna-reverse-course-flu-vaccine/